Johnson & Johnson Innovation and its Janssen, Inc. in Canada affiliate have entered collaborations with two early-stage drug technology development centers, NEOMED in Montreal and MaRS Innovation in Toronto, to identify and advance promising bio/pharmaceutical technologies.
Technical experts from the J&J Innovation Center in Boston, MA will work with NEOMED and MaRS to identify investment opportunities emerging from validated scientific research discoveries within their communities of academic institutions and biotechnology companies.
“We know from our history of engagement that the Canadian bio/pharmaceutical environment is one of the most vibrant in the world,” said Robert Urban, head of the J&J Innovation Center, Boston. “These new collaborations will allow us to potentially advance important new clinical candidates against disease.”
“Quebec and Ontario are home to numerous world-class academic and biomedical research enterprises,” said Paul Kershaw, vice president of Medical Affairs, Janssen Inc. in Canada. “These new relationships with NEOMED and MaRS Innovation are an extension of our commitment to Canada’s innovative research community.”
NEOMED is a not-for-profit, public-private Pharma alliance dedicated to drug discovery and development. MaRS Innovation is the commercialization agent for Ontario’s discovery pipeline from 16 academic institutions.